SCHEMBL4918965

SCHEMBL4918965

CC(=O)Nc1cccc(CNc2nc(Nc3cccc(NS(C)(=O)=O)c3)nc3[nH]cnc23)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 10/20 0.50
NEK2 P51955 2/20 0.44
PIP4K2A P48426 1/20 0.42
PIP4K2B P78356 1/20 0.42
ROCK1 Q13464 2/20 0.41
AURKB Q96GD4 2/20 0.41
PLK4 O00444 1/20 0.41
CHEK1 O14757 1/20 0.41
DAPK3 O43293 1/20 0.41
DYRK3 O43781 1/20 0.41
JAK2 O60674 1/20 0.41
ROCK2 O75116 1/20 0.41
PRKD3 O94806 1/20 0.41
MAP4K4 O95819 1/20 0.41
CHEK2 O96017 1/20 0.41
PRKCG P05129 1/20 0.41
CDK1 P06493 1/20 0.41
ROS1 P08922 1/20 0.41
PIM1 P11309 1/20 0.41
PRKACA P17612 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4917809 0.91 ALDH1A1 (0.46) PTK2MAPK1CLK4PDE5ACYP3A4
SCHEMBL4919702 0.89 PDE5A (0.42) PTK2CDK1MAPK1CLK4PDE5A
SCHEMBL4916374 0.88 PDE5A (0.50) PTK2MAPK1CLK4PDE5ACYP3A4
SCHEMBL4912787 0.87 PTK2 (0.51) PTK2CDK1PDE5ACYP3A4
SCHEMBL4909992 0.87 PDE5A (0.43) PTK2NEK2MAPK1CLK4PDE5A
SCHEMBL4920046 0.87 PTK2 (0.48) PTK2PDE5A
SCHEMBL4914819 0.86 PDE5A (0.44) PTK2JAK2CLK4PDE5ACYP3A4
SCHEMBL4917738 0.85 MAPT (0.46) PTK2ROCK1CDK1MAPK1PDE5A
SCHEMBL4917319 0.85 PTK2 (0.45) PTK2PDE5A
SCHEMBL4920844 0.85 CYP1A2 (0.55) PTK2JAK2MAPK1KDRCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK PTK2 1036/4885NEK2 609/4885PIP4K2A 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.